Psoriasis disease manifestation occurs only in a portion of subjects undergone anti-PD-1 therapies for advanced solid tumors, with an incidence rate of ~ 4.3% in patients developing ircAEs (46). This evidence concerns the gene PDCD1 and psoriasis.